A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias

This phase I study is testing the safety of a chemotherapy combination called Hyper-CVAD together with venetoclax in children, teenagers, and young adults with relapsed or treatment-resistant acute lymphoid leukemia (a blood cancer) that has come back or failed to respond to previous therapies. **You may be eligible if...** - You are a pediatric, adolescent, or young adult patient - You have relapsed or refractory acute leukemia of the lymphoid type (including bi-phenotypic or undifferentiated leukemia) - At least 5% of your bone marrow or blood consists of leukemia cells **You may NOT be eligible if...** - Your leukemia is of a different type (e.g., purely myeloid) - You have serious organ problems that prevent safe treatment with intensive chemotherapy Talk to your doctor to see if this trial is right for you.